Immunotoxicity of Therapeutic Antibodies and Nanoparticles
- Publication type:
- Journal article
- Metadata:
-
- Autoren
- Nadire Ozenver
- Thomas Efferth
- Autoren-URL
- https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=fis-test-1&SrcAuth=WosAPI&KeyUT=WOS:000527295200003&DestLinkType=FullRecord&DestApp=WOS_CPL
- DOI
- 10.1615/CritRevImmunol.2020033236
- eISSN
- 2162-6472
- Externe Identifier
- Clarivate Analytics Document Solution ID: LF3BB
- PubMed Identifier: 32421979
- ISSN
- 1040-8401
- Ausgabe der Veröffentlichung
- 1
- Zeitschrift
- CRITICAL REVIEWS IN IMMUNOLOGY
- Schlüsselwörter
- monoclonal antibody
- nanotherapy
- immunomodulation
- Paginierung
- 53 - 74
- Datum der Veröffentlichung
- 2020
- Status
- Published
- Titel
- Immunotoxicity of Therapeutic Antibodies and Nanoparticles
- Sub types
- Article
- Ausgabe der Zeitschrift
- 40
Data source: Web of Science (Lite)
- Other metadata sources:
-
- Autoren
- Nadire Özenver
- Thomas Efferth
- DOI
- 10.1615/critrevimmunol.2020033236
- ISSN
- 1040-8401
- Ausgabe der Veröffentlichung
- 1
- Zeitschrift
- Critical Reviews in Immunology
- Sprache
- en
- Paginierung
- 53 - 74
- Datum der Veröffentlichung
- 2020
- Status
- Published
- Herausgeber
- Begell House
- Herausgeber URL
- http://dx.doi.org/10.1615/critrevimmunol.2020033236
- Datum der Datenerfassung
- 2020
- Titel
- Immunotoxicity of Therapeutic Antibodies and Nanoparticles
- Ausgabe der Zeitschrift
- 40
Data source: Crossref
- Abstract
- Therapeutic antibodies and nanotherapeutic drugs are of great concern due to their widespread use against numerous diseases worldwide. They are frequently used for targeted therapy under the assumption that they cause fewer side effects than nontargeted drugs. Despite their specificity and particular design for therapeutic actions, they might still exhibit unintended adverse effects in the immune system. Immunotoxicity reactions are mediated by immunomodulation, including immunostimulation and immunosuppression. The present review gives an overview on the adverse immunotoxic effects induced by therapeutic antibodies as well as nanotherapeutic drugs. In this context, future methods combining more efficient drug design with better tolerability and fewer adverse effects are discussed to ensure improved safety in the engineering of therapeutic antibodies and nanotherapeutics.
- Addresses
- Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, Johannes Gutenberg University, Mainz, Germany; Hacettepe University, Faculty of Pharmacy, Department of Pharmacognosy, Ankara, Turkey.
- Autoren
- Nadire Özenver
- Thomas Efferth
- DOI
- 10.1615/critrevimmunol.2020033236
- Externe Identifier
- PubMed Identifier: 32421979
- Open access
- false
- ISSN
- 1040-8401
- Ausgabe der Veröffentlichung
- 1
- Zeitschrift
- Critical reviews in immunology
- Schlüsselwörter
- Immune System
- Animals
- Humans
- Antibodies
- Cytotoxicity, Immunologic
- Drug Design
- Nanoparticles
- Immunomodulation
- Bioengineering
- Drug-Related Side Effects and Adverse Reactions
- Sprache
- eng
- Medium
- Paginierung
- 53 - 74
- Datum der Veröffentlichung
- 2020
- Status
- Published
- Datum der Datenerfassung
- 2020
- Titel
- Immunotoxicity of Therapeutic Antibodies and Nanoparticles.
- Sub types
- Research Support, Non-U.S. Gov't
- Review
- Journal Article
- Ausgabe der Zeitschrift
- 40
Data source: Europe PubMed Central
- Abstract
- Therapeutic antibodies and nanotherapeutic drugs are of great concern due to their widespread use against numerous diseases worldwide. They are frequently used for targeted therapy under the assumption that they cause fewer side effects than nontargeted drugs. Despite their specificity and particular design for therapeutic actions, they might still exhibit unintended adverse effects in the immune system. Immunotoxicity reactions are mediated by immunomodulation, including immunostimulation and immunosuppression. The present review gives an overview on the adverse immunotoxic effects induced by therapeutic antibodies as well as nanotherapeutic drugs. In this context, future methods combining more efficient drug design with better tolerability and fewer adverse effects are discussed to ensure improved safety in the engineering of therapeutic antibodies and nanotherapeutics.
- Autoren
- Nadire Özenver
- Thomas Efferth
- Autoren-URL
- https://www.ncbi.nlm.nih.gov/pubmed/32421979
- DOI
- 10.1615/CritRevImmunol.2020033236
- ISSN
- 1040-8401
- Ausgabe der Veröffentlichung
- 1
- Zeitschrift
- Crit Rev Immunol
- Schlüsselwörter
- Animals
- Antibodies
- Bioengineering
- Cytotoxicity, Immunologic
- Drug Design
- Drug-Related Side Effects and Adverse Reactions
- Humans
- Immune System
- Immunomodulation
- Nanoparticles
- Sprache
- eng
- Country
- United States
- Paginierung
- 53 - 74
- PII
- 15281ffe75123d72,117f594e4b28b2fc
- Datum der Veröffentlichung
- 2020
- Status
- Published
- Datum, an dem der Datensatz öffentlich gemacht wurde
- 2020
- Titel
- Immunotoxicity of Therapeutic Antibodies and Nanoparticles.
- Sub types
- Journal Article
- Research Support, Non-U.S. Gov't
- Review
- Ausgabe der Zeitschrift
- 40
Data source: PubMed
- Beziehungen:
- Property of